116 related articles for article (PubMed ID: 30396926)
1. Modified Nucleosides - Molecular Markers Suitable for Small-volume Cancer?
Opitz P; Herbarth O; Seidel A; Boehm A; Fischer M; Mozet C; Dietz A; Wichmann G
Anticancer Res; 2018 Nov; 38(11):6113-6119. PubMed ID: 30396926
[TBL] [Abstract][Full Text] [Related]
2. Modified nucleosides as biomarkers for early cancer diagnose in exposed populations.
Seidel A; Seidel P; Manuwald O; Herbarth O
Environ Toxicol; 2015 Jul; 30(8):956-67. PubMed ID: 24615900
[TBL] [Abstract][Full Text] [Related]
3. The volatilome - investigation of volatile organic metabolites (VOM) as potential tumor markers in patients with head and neck squamous cell carcinoma (HNSCC).
Opitz P; Herbarth O
J Otolaryngol Head Neck Surg; 2018 Jul; 47(1):42. PubMed ID: 29970175
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of urinary nucleosides by high-performance liquid chromatography.
Liebich HM; Di Stefano C; Wixforth A; Schmid HR
J Chromatogr A; 1997 Feb; 763(1-2):193-7. PubMed ID: 9129323
[TBL] [Abstract][Full Text] [Related]
5. Multilayer perceptron tumour diagnosis based on chromatography analysis of urinary nucleosides.
Seidel P; Seidel A; Herbarth O
Neural Netw; 2007 Jul; 20(5):646-51. PubMed ID: 17275256
[TBL] [Abstract][Full Text] [Related]
6. Modified nucleosides: an accurate tumour marker for clinical diagnosis of cancer, early detection and therapy control.
Seidel A; Brunner S; Seidel P; Fritz GI; Herbarth O
Br J Cancer; 2006 Jun; 94(11):1726-33. PubMed ID: 16685264
[TBL] [Abstract][Full Text] [Related]
7. Artificial neural network classification based on high-performance liquid chromatography of urinary and serum nucleosides for the clinical diagnosis of cancer.
Yang J; Xu G; Kong H; Zheng Y; Pang T; Yang Q
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Nov; 780(1):27-33. PubMed ID: 12383477
[TBL] [Abstract][Full Text] [Related]
8. Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers.
Gross ND; Boyle JO; Morrow JD; Williams MK; Moskowitz CS; Subbaramaiah K; Dannenberg AJ; Duffield-Lillico AJ
Clin Cancer Res; 2005 Aug; 11(16):6087-93. PubMed ID: 16115954
[TBL] [Abstract][Full Text] [Related]
9. Bioinformatical evaluation of modified nucleosides as biomedical markers in diagnosis of breast cancer.
Bullinger D; Fröhlich H; Klaus F; Neubauer H; Frickenschmidt A; Henneges C; Zell A; Laufer S; Gleiter CH; Liebich H; Kammerer B
Anal Chim Acta; 2008 Jun; 618(1):29-34. PubMed ID: 18501242
[TBL] [Abstract][Full Text] [Related]
10. Elevated levels of 1-hydroxypyrene and N'-nitrosonornicotine in smokers with head and neck cancer: A matched control study.
Khariwala SS; Carmella SG; Stepanov I; Fernandes P; Lassig AA; Yueh B; Hatsukami D; Hecht SS
Head Neck; 2013 Aug; 35(8):1096-100. PubMed ID: 22807150
[TBL] [Abstract][Full Text] [Related]
11. Urinary nucleosides as potential tumor markers evaluated by learning vector quantization.
Dieterle F; Müller-Hagedorn S; Liebich HM; Gauglitz G
Artif Intell Med; 2003 Jul; 28(3):265-79. PubMed ID: 12927336
[TBL] [Abstract][Full Text] [Related]
12. Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring.
Feng B; Zheng MH; Zheng YF; Lu AG; Li JW; Wang ML; Ma JJ; Xu GW; Liu BY; Zhu ZG
J Gastroenterol Hepatol; 2005 Dec; 20(12):1913-9. PubMed ID: 16336453
[TBL] [Abstract][Full Text] [Related]
13. Urinary modified nucleosides as novel biomarkers for diagnosis and prognostic monitoring of urothelial bladder cancer.
Zhang YR; Shi L; Wu H; Tang DD; Wang SM; Liu HM; Zhang LR; Song DK
Tumori; 2014; 100(6):660-6. PubMed ID: 25688500
[TBL] [Abstract][Full Text] [Related]
14. Excretion pattern investigation of urinary normal and modified nucleosides of breast cancer patients by RP-HPLC and factor analysis method.
Xu G; Schmid HR; Lu X; Liebich HM; Lu P
Biomed Chromatogr; 2000 Nov; 14(7):459-63. PubMed ID: 11113924
[TBL] [Abstract][Full Text] [Related]
15. Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients.
Frickenschmidt A; Frohlich H; Bullinger D; Zell A; Laufer S; Gleiter CH; Liebich H; Kammerer B
Biomarkers; 2008 Jun; 13(4):435-49. PubMed ID: 18484357
[TBL] [Abstract][Full Text] [Related]
16. Reversed-phase high-performance liquid chromatographic investigation of urinary normal and modified nucleosides of cancer patients.
Xu G; Di Stefano C; Liebich HM; Zhang Y; Lu P
J Chromatogr B Biomed Sci Appl; 1999 Sep; 732(2):307-13. PubMed ID: 10517352
[TBL] [Abstract][Full Text] [Related]
17. Two approaches for determining the urinary excretion patterns of nucleosides--HPLC and CE.
Xu G; Lu X; Zhang Y; Lu P; Di Stefano C; Lehmann R; Liebich H
Se Pu; 1999 Mar; 17(2):97-101. PubMed ID: 12549143
[TBL] [Abstract][Full Text] [Related]
18. Patterns of urinary excretion of modified nucleosides.
Gehrke CW; Kuo KC; Waalkes TP; Borek E
Cancer Res; 1979 Apr; 39(4):1150-3. PubMed ID: 421198
[TBL] [Abstract][Full Text] [Related]
19. Comparison of RP-HPLC columns used for determination of nucleoside metabolic patterns in urine of cancer patients.
Waszczuk-Jankowska M; Markuszewski MJ; Markuszewski M; Kaliszan R
Bioanalysis; 2012 Jun; 4(10):1185-94. PubMed ID: 22651562
[TBL] [Abstract][Full Text] [Related]
20. [Investigation of urinary nucleosides excretion of intestinal cancer patients by reversed-phase high performance liquid chromatography].
Zheng YF; Chen YJ; Pang T; Shi XZ; Kong HW; Lü S; Yang Q; Xu GW
Se Pu; 2002 Nov; 20(6):498-501. PubMed ID: 12682995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
